 xxxd252xxx  is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase ii study.  patients with advanced, incurable thyroid cancer not amenable to surgery or radioactive iodine ((131)i) therapy have few satisfactory therapeutic options. this multi-institutional study assessed the activity and safety of  xxxd252xxx , an oral, potent, and selective inhibitor of  xxxg2413xxx  receptors ( xxxg800xxx   xxxg802xxx   xxxg1274xxx ) 1, 2, and 3 in patients with advanced thyroid cancer.